About: Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
Creator	Bottieau, Emmanuel Piérard, Denis Bossuyt, Nathalie Bafort, Kristof Belkhir, Leïla Catteau, Lucy Colombie, Vincent Dauby, Nicolas De Munter, Paul Deblonde, Jessika Delmarcelle, Didier Delvallee, Mélanie Demeester, Rémy Dugernier, Thierry Duysburgh, Els Goetghebeur, Els Goethem, Nina Hautekiet, Joris Holemans, Xavier Kerzmann, Benjamin Machurot, Pierre Minette, Philippe Minon, Jean-Marc Mokrane, Saphia Montourcy, Marion Nachtergal, Catherine Noirhomme, Séverine Praet, Jens Rossi, Camelia Schirvel, Carole Sermijn, Erica Staelens, Frank Triest, Filip Van Beckhoven, Dominique Van Oyen, Herman Vanhoenacker, Anke Willems, Elise Wyndham-Thomas, Chloé Belgian, Caprasse, Philippe Van Ierssel, Sabrina Verstraete, Roeland
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Hydroxychloroquine (HCQ) has been largely used and investigated as therapy of COVID-19 across various settings, at total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (2400 mg in total over five days) was recommended for hospitalized patients with COVID-19. METHODS: We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ alone and supportive care (HCQ group) were compared to patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. RESULTS: Of 8075 patients with complete discharge data on 24(th) of May and diagnosed before the 1(st) of May, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, the mortality was lower in the HCQ group compared to the no-HCQ group (adjusted hazard ratio [HR] 0.684, 95% confidence interval [CI] 0.617–0.758). Compared to the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤ 5 days (n=3975) and > 5 days (n=3487) after symptom onset (adjusted HR 0.701, 95% CI 0.617–0.796 and adjusted HR 0.647, 95% CI 0.525–0.797, respectively). CONCLUSIONS: Compared to supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalized patients with COVID-19 diagnosed and treated early or later after symptom onset.
has issue date	2020-08-24(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.106144
bibo:pmid	32853673
has license	no-cc
sha1sum (hex)	a2a17c20311ab4b3675c980b00a1ac492934df35
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.106144
resource representing a document's title	Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
has PubMed Central identifier	PMC7444610
has PubMed identifier	32853673
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:a2a17c20311ab4b3675c980b00a1ac492934df35#body_text
is schema:about of	named entity 'TOTAL' named entity 'OFF-LABEL USE' named entity 'LOW-DOSE' named entity 'BELGIUM' named entity 'BACKGROUND' named entity 'Hydroxychloroquine' named entity 'Mortality' named entity 'Study' named entity 'Low-dose' named entity 'Observational Study' named entity 'Hydroxychloroquine' named entity 'infection' named entity 'Hydroxychloroquine' named entity 'causative agent' named entity 'LDH' named entity 'CRP' named entity 'HCQ' named entity 'obesity' named entity 'SLE' named entity 'HCQ' named entity 'missing data' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'retrospective studies' named entity 'cumulative incidence' named entity 'anti-viral' named entity 'sulphate' named entity 'ICU' named entity 'early diagnosis' named entity 'ventilation support' named entity 'CRP' named entity 'early diagnosis' named entity 'neurological' named entity 'lactate' named entity 'COVID' named entity 'COVID' named entity 'diabetes' named entity 'HCQ' named entity 'robust standard errors' named entity 'off-label'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software